BRPI0414812A - method of inhibiting the expression of multidrug resistant genes and inhibiting the production of proteins resulting from the expression of such genes, thereby improving the effectiveness of chemotherapeutic agents for treating cancer - Google Patents
method of inhibiting the expression of multidrug resistant genes and inhibiting the production of proteins resulting from the expression of such genes, thereby improving the effectiveness of chemotherapeutic agents for treating cancerInfo
- Publication number
- BRPI0414812A BRPI0414812A BRPI0414812-6A BRPI0414812A BRPI0414812A BR PI0414812 A BRPI0414812 A BR PI0414812A BR PI0414812 A BRPI0414812 A BR PI0414812A BR PI0414812 A BRPI0414812 A BR PI0414812A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibiting
- expression
- genes
- effectiveness
- production
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 9
- 230000002401 inhibitory effect Effects 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 239000002246 antineoplastic agent Substances 0.000 title abstract 4
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 abstract 4
- 210000004102 animal cell Anatomy 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
"MéTODO DE INIBIR A EXPRESSãO DE GENES RESISTENTES A MúLTIPLOS MEDICAMENTOS E DE INIBIR A PRODUçãO DE PROTEìNAS RESULTANTES DA EXPRESSãO DE TAIS GENES, MELHORANDO ASSIM A EFETIVIDADE DOS AGENTES QUIMIOTERáPICOS PARA TRATAR CáNCERES". A presente invenção fornece, em um aspecto, um método de inibir a expressão de um gene resistente a múltiplos medicamentos em uma célula animal que compreende administrar a um animal uma quantidade eficaz de, pelo menos, um inibidor da absorção do colesterol. Em um outro aspecto, é fornecido um método de inibir a produção de uma proteina expressa por um gene resistente a múltiplos medicamentos em uma célula animal que compreende administrar a um animal uma quantidade eficaz de, pelo menos, um inibidor da absorção do colesterol. Em um outro aspecto, a presente invenção fornece um método de melhorar a efetividade de um agente quimioterápico em um animal com câncer, que compreende administrar ao dito animal uma quantidade eficaz do agente quimioterápico e, pelo menos, um inibidor da absorção do colesterol. Além disso, foram fornecidas composições e estojos para uso no tratamento do câncer que compreende, pelo menos, um agente quimioterápico e, pelo menos, um inibidor da absorção do colesterol."METHOD OF INHIBITING EXPRESSION OF GENES RESISTANT TO MULTIPLE MEDICINAL PRODUCTS AND INHIBITING THE PRODUCTION OF PROTEINS RESULTING FROM EXPRESSION OF SUCH GENES, IMPROVING THE EFFECTIVENESS OF CHEMOTHERAPIC AGENTS". The present invention provides, in one aspect, a method of inhibiting the expression of a multidrug resistant gene in an animal cell comprising administering to an animal an effective amount of at least one cholesterol absorption inhibitor. In another aspect, there is provided a method of inhibiting the production of a protein expressed by a multidrug resistant gene in an animal cell comprising administering to an animal an effective amount of at least one cholesterol absorption inhibitor. In another aspect, the present invention provides a method of enhancing the effectiveness of a chemotherapeutic agent in a cancer animal comprising administering to said animal an effective amount of the chemotherapeutic agent and at least one cholesterol absorption inhibitor. In addition, compositions and kits for use in the treatment of cancer comprising at least one chemotherapeutic agent and at least one cholesterol absorption inhibitor have been provided.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67305103A | 2003-09-26 | 2003-09-26 | |
| PCT/CA2004/001697 WO2005030225A2 (en) | 2003-09-26 | 2004-09-27 | Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0414812A true BRPI0414812A (en) | 2006-11-14 |
Family
ID=34393484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0414812-6A BRPI0414812A (en) | 2003-09-26 | 2004-09-27 | method of inhibiting the expression of multidrug resistant genes and inhibiting the production of proteins resulting from the expression of such genes, thereby improving the effectiveness of chemotherapeutic agents for treating cancer |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1677803A2 (en) |
| JP (1) | JP2007524651A (en) |
| KR (1) | KR20060135615A (en) |
| CN (1) | CN1874780A (en) |
| AU (1) | AU2004275444A1 (en) |
| BR (1) | BRPI0414812A (en) |
| CA (1) | CA2540364A1 (en) |
| RU (1) | RU2006114049A (en) |
| WO (1) | WO2005030225A2 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE450526T1 (en) | 2005-06-20 | 2009-12-15 | Schering Corp | PIPERIDINE DERIVATIVES SUITABLE AS ANTAGONISTS OF HISTAMINE H3 |
| KR20160066557A (en) * | 2008-03-14 | 2016-06-10 | 제넨테크, 인크. | Genetic variations associated with drug resistance |
| CN102552284A (en) * | 2011-12-13 | 2012-07-11 | 陕西师范大学 | Application of ergosterol in preparation of tumor multidrug resistance reversing medicines |
| CA2939305A1 (en) | 2014-02-27 | 2015-09-03 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods |
| CA2947290A1 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| JP2018515491A (en) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | Dihydro-2H-benzo [b] [1,4] oxazinesulfonamide and related compounds for use as RORγ agonists and disease therapies |
| EP3307738B1 (en) | 2015-06-11 | 2022-04-20 | The Regents of the University of Michigan | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| CN106420768B (en) * | 2015-08-13 | 2018-12-28 | 广州中医药大学第二附属医院 | Application of the Cheng ketone sterol as P- glycoprotein inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995017192A1 (en) * | 1993-12-22 | 1995-06-29 | The Salk Institute For Biological Studies | Methods for reducing multidrug resistance |
| EP1285914B1 (en) * | 2001-08-13 | 2007-12-19 | PheneX Pharmaceuticals AG | Nr1h4 nuclear receptor binding compounds |
| DE60334711D1 (en) * | 2002-07-30 | 2010-12-09 | Karykion Inc | EZETIMIB COMPOSITIONS AND METHOD FOR THE TREATMENT OF CHOLESTERIN-ASSOCIATED GOOD AND EVIL TUMORS |
-
2004
- 2004-09-27 CA CA002540364A patent/CA2540364A1/en not_active Abandoned
- 2004-09-27 WO PCT/CA2004/001697 patent/WO2005030225A2/en not_active Ceased
- 2004-09-27 CN CNA2004800316973A patent/CN1874780A/en active Pending
- 2004-09-27 AU AU2004275444A patent/AU2004275444A1/en not_active Abandoned
- 2004-09-27 RU RU2006114049/15A patent/RU2006114049A/en unknown
- 2004-09-27 JP JP2006527239A patent/JP2007524651A/en active Pending
- 2004-09-27 KR KR1020067005929A patent/KR20060135615A/en not_active Withdrawn
- 2004-09-27 BR BRPI0414812-6A patent/BRPI0414812A/en not_active Application Discontinuation
- 2004-09-27 EP EP04761853A patent/EP1677803A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007524651A (en) | 2007-08-30 |
| WO2005030225A3 (en) | 2005-05-26 |
| EP1677803A2 (en) | 2006-07-12 |
| WO2005030225A2 (en) | 2005-04-07 |
| RU2006114049A (en) | 2007-11-20 |
| AU2004275444A1 (en) | 2005-04-07 |
| KR20060135615A (en) | 2006-12-29 |
| CA2540364A1 (en) | 2005-04-07 |
| CN1874780A (en) | 2006-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0412885A (en) | polypeptides, specific binding agents, nucleic acid molecules and isolated cell lines, host cells, compositions and antigen binding domain or antibody and methods of treating cancer and solid tumor in a patient, detecting growth factor level hepatocyte (hgf) in a sample, obtaining antibody and inhibiting hgf binding to met and decreasing or preventing the binding of any of the hepatocyte growth factor (hgf) -specific binding agents | |
| BRPI0509172A (en) | at least one chemical entity, pharmaceutical composition, methods for treating a patient, inhibiting at least one enzyme using atp, and treating at least one disease, use of at least one chemical entity, and method for the manufacture of a medicament | |
| BR0206381A (en) | Fumaric acid derivatives as nf-kappab inhibitor | |
| BRPI0412909A (en) | use of rnai inhibiting parp activity for the manufacture of a cancer medicine | |
| BRPI0311323B8 (en) | sglt2 c-aryl glycoside inhibitor compound, pharmaceutical composition and combination | |
| CY1115870T1 (en) | 1,2,4-OXIADEZOLO Benzoic Acid Compounds and Their Use for Non-Nutritional Suppression and Illness Therapy | |
| BR9913855A (en) | 1-2-3-4- tetrahydroquinolines substituted in position 2 and substituted in position 4 with amino as cetp inhibitors | |
| BRPI0407375A (en) | Methods for treating pain by administering a neural growth factor antagonist and a nsaid and compositions containing same | |
| BR0312464A (en) | Tyrosine kinase inhibitors | |
| BR9502707A (en) | Compound pharmaceutical composition and method for treating a condition | |
| BR0115109A (en) | Therapeutic agents and methods of their use for angiogenesis modulation | |
| BR0011000A (en) | Methods to prevent or treat a disease associated with ab amyloid deposits in a patient's brain, to evaluate an antibody for the removal activity of a biological entity physically associated with an antigen and to detect an amyloid deposit in a patient, pharmaceutical composition, and, diagnostic set | |
| EP1562897A4 (en) | PHENYLCARBOXAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
| BR0016935A (en) | Use of fumaric acid derivatives for treatment of mitochondrial diseases | |
| BR0116370A (en) | Compound, pharmaceutical composition, use of a compound, and method of treating an hppar-mediated disease or condition in a patient. | |
| JO2373B1 (en) | W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors | |
| BR0304648A (en) | Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia | |
| PT1143955E (en) | COMBINATION OF FBPASE INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | |
| BRPI0408466A (en) | pharmaceutical compositions of cetp inhibitors and use of said inhibitors | |
| BR0312768A (en) | 5-Ariltetrazole compounds, compositions thereof and uses thereof | |
| DE60332363D1 (en) | OLIGONUCLEOTIDES FOR THE TREATMENT OF PROSTATE CANCER AND OTHER CANCER DISEASES | |
| BRPI0409926A (en) | saposin c-dops: an antitumor agent | |
| BRPI0411176A (en) | pharmaceutical combination consisting of modafinil and another drug | |
| BRPI0414812A (en) | method of inhibiting the expression of multidrug resistant genes and inhibiting the production of proteins resulting from the expression of such genes, thereby improving the effectiveness of chemotherapeutic agents for treating cancer | |
| BR0211936A (en) | Use of glycosamine and a selective cyclooxygenase-2 inhibitor or prodrug thereof in the manufacture of a medicament as well as a pharmaceutical composition and kit comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |